Is Age Just a "Number" When Evaluating the Efficacy and Safety of Triple-Inhaled Therapy in COPD?

Affiliations

¹ Medicine, Pulmonary/Critical Care Division, UT Health San Antonio South Texas Veterans Health Care System, San Antonio, TX. Electronic address: adamssg@uthscsa.edu.
² Medicine, Pulmonary/Critical Care Division, UT Health San Antonio South Texas Veterans Health Care System, San Antonio, TX.

Editorial

Sandra G Adams et al. Chest. 2021 Mar.

. 2021 Mar;159(3):895-896.

doi: 10.1016/j.chest.2020.10.022.

¹ Medicine, Pulmonary/Critical Care Division, UT Health San Antonio South Texas Veterans Health Care System, San Antonio, TX. Electronic address: adamssg@uthscsa.edu.
² Medicine, Pulmonary/Critical Care Division, UT Health San Antonio South Texas Veterans Health Care System, San Antonio, TX.

No abstract available

Comment on

Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA. Hanania NA, et al. Chest. 2021 Mar;159(3):985-995. doi: 10.1016/j.chest.2020.09.253. Epub 2020 Oct 5. Chest. 2021. PMID: 33031829 Clinical Trial.